Kazachstania turicensis CAU Y1706 ameliorates atopic dermatitis by regulation of the gut-skin axis

Abstract

Atopic dermatitis (AD) causes chronic inflammatory skin disease that results in a considerable economic expense and social burden. Certain Lactobacillus strains ameliorate AD, but the effects of probiotic yeast on AD have not been investigated to date. In this study, we isolated Kazachstania turicensis CAU Y1706, commonly known as a kefir yeast, and evaluated its mitigating effects using an ovalbumin-sensitized AD mouse model. Overall, K. turicensis CAU Y1706 was generally effective against AD. Oral administration of K. turicensis CAU Y1706 suppressed T helper type 2 immune response factors by regulatory T cells and upregulation of T helper type 1 cytokine levels. Kazachstania turicensis CAU Y1706 also reduced IgE levels as well as the number of eosinophil and mast cells. Furthermore, feces from K. turicensis CAU Y1706-treated mice had more butyrate-producing bacteria, such as Lactobacillus, Bacteroides, Ruminococcus, and Akkermansia, although the level of Fecalibacterium was significantly reduced. Therefore, K. turicensis CAU Y1706 modulates immune responses as well as gut microbiota, thus indicating that it has potential for application as a supplement for alleviation of AD.